Valuation: Onconic Therapeutics Inc.

Market Cap 530B 389M 349M 319M 291M 548M 36.56B 566M 3.84B 1.53B 19.51B 1.46B 1.43B 61.58B P/E 2024
-16.5x
P/E 2025 56.2x
Enterprise Value 478B 350M 314M 287M 262M 494M 32.93B 509M 3.46B 1.38B 17.57B 1.32B 1.29B 55.47B EV / Sales 2024
9.02x
EV / Sales 2025 15.3x
Free-Float
50.62%
Yield 2024 *
-
Yield 2025 -
1 day-3.23%
1 week-3.55%
Current month-3.55%
1 month-24.69%
3 months-16.87%
6 months-42.89%
Current year-40.26%
1 week 11,100
Extreme 11100
12,800
1 month 11,100
Extreme 11100
15,170
Current year 8,790
Extreme 8790
28,900
1 year 8,790
Extreme 8790
28,900
3 years 3,137.5
Extreme 3137.5
28,900
5 years 3,137.5
Extreme 3137.5
28,900
10 years 3,137.5
Extreme 3137.5
28,900
Manager TitleAgeSince
Chief Executive Officer 59 01/01/2020
Director of Finance/CFO 50 01/01/2020
Chief Tech/Sci/R&D Officer 59 -
Director TitleAgeSince
Director/Board Member 50 01/01/2020
Director/Board Member 59 01/01/2020
Director/Board Member 44 26/03/2024
Date Insider Type Main position Quantity % Market Cap. Importance
22/4/25 Exercice 50,000 0.4595%
18/4/25 Exercice

Chief Technology Officer

12,500 0.1149%
17/4/25 Exercice

Chief Financial Officer

18,100 0.1663%
Change 5-day change 1-year change 3-year change Capi.($)
-3.23%-3.55%-15.24% - 389M
-4.83%+3.51%+55.00%+63.79% 66.7B
+0.02%+1.07%+11.72%+75.63% 56.88B
-1.34%+2.98%+25.08%+100.18% 56.53B
+5.09%+9.89%+27.19%+105.85% 46.49B
+2.62%+1.68%+29.16%+35.86% 44.8B
+8.24%+0.51%+215.16%+794.74% 41.59B
-1.86%+10.13%+28.14%+55.48% 35.35B
-2.97%-9.84%+90.91%+73.49% 33.29B
+5.19%+1.62%-39.69%+368.87% 25.1B
Average +0.69%+1.81%+42.74%+185.99% 40.71B
Weighted average by Cap. +0.65%+3.07%+49.84%+165.88%

Financials

2024 2025
Net sales 14.84B 10.88M 9.76M 8.92M 8.14M 15.34M 1.02B 15.82M 108M 42.87M 546M 40.84M 39.97M 1.72B 53.39B 39.15M 35.12M 32.09M 29.3M 55.2M 3.68B 56.94M 387M 154M 1.96B 147M 144M 6.2B
Net income -8.09B -5.93M -5.32M -4.86M -4.44M -8.37M -558M -8.63M -58.63M -23.38M -298M -22.27M -21.8M -940M 15.78B 11.57M 10.38M 9.49M 8.66M 16.32M 1.09B 16.83M 114M 45.6M 581M 43.45M 42.51M 1.83B
Net Debt -42.69B -31.31M -28.08M -25.66M -23.42M -44.13M -2.94B -45.53M -309M -123M -1.57B -118M -115M -4.96B -52.61B -38.58M -34.6M -31.62M -28.87M -54.39M -3.63B -56.1M -381M -152M -1.94B -145M -142M -6.11B
Projected Income Statement - Annual - Onconic Therapeutics Inc.
Logo Onconic Therapeutics Inc.
Onconic Therapeutics Inc is a Korea-based company principally engaged in the new drugs research and development business. The Company mainly develops new drugs and treatments in the acid-related diseases, digestive diseases and anticancer fields based on small molecules. The Company’s products include acid-related disease treatment drug Zastaprazan and synthetic lethal deoxyribonucleic acid (DNA) damage repair inhibitor anticancer drug Nesuparib.
Employees
-
Date Price Change Volume
06/11/26 KRW 11,680.00 -3.23% 186,137
05/11/26 KRW 12,070.00 -0.49% 160,135
04/11/26 KRW 12,130.00 +2.80% 163,334
03/11/26 KRW 11,800.00 -4.76% 112,492
02/11/26 KRW 12,390.00 +2.31% 104,979
  1. Stock Market
  2. Stocks
  3. A476060 Stock